Role of inflammation in myocardial infarction with non-obstructive coronary arteries

doi:10.20039/j.cnki.10073949.2023.06.011

Home > Archive>Volume 31, Issue 6, 2023 >533-538. DOI:10.20039/j.cnki.10073949.2023.06.011

Role of inflammation in myocardial infarction with non-obstructive coronary arteries
DOI:
                        10.20039/j.cnki.10073949.2023.06.011
                    
CSTR:
                        
                    
Author:
                        FEI SifanFEI Sifan
The First Peoples Hospital of Changzhou & Department of Cardiovascular Medicine, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
JIA FangJIA Fang
The First Peoples Hospital of Changzhou & Department of Cardiovascular Medicine, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site
ZHANG ShengZHANG Sheng
The First Peoples Hospital of Changzhou & Department of Cardiovascular Medicine, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, China
Find this author on All Journals
Find this author on BaiDu
Search for this author on this site

                    
Affiliation:The First People's Hospital of Changzhou & Department of Cardiovascular Medicine, Third Affiliated Hospital of Soochow University, Changzhou, Jiangsu 213000, China)
Clc Number:R54
Fund Project:

Article

Figures

Metrics

Reference [42]

Cited by

Materials

Comments

Abstract:

Myocardial infarction with non-obstructive coronary arteries (MINOCA) is a special kind of myocardial infarction, and its prognosis is related to different causes. This review summarized the correlation between inflammation and various causes of MINOCA, and the correlation between inflammatory factors such as C-reactive protein, neutrophil-to-lymphocyte ratio, interleukin-6 and prognosis of MINOCA.

Key words:myocardial infarction with non-obstructive coronary arteries; inflammation; prognosis

Reference

[1] LINDAHL B, BARON T, ALBERTUCCI M, PRATI F.Myocardial infarction with non-obstructive coronary artery disease.EuroIntervention, 1,7(11):e875-e887.

[2] AGEWALL S, BELTRAME J F, REYNOLDS H R, et al.ESC working group position paper on myocardial infarction with non-obstructive coronary arteries.Eur Heart J, 7,8(3):143-153.

[3] SAFDAR B, SPATZ E S, DREYER R P, et al.Presentation, clinical profile, and prognosis of young patients with myocardial infarction with nonobstructive coronary arteries (MINOCA):results from the VIRGO study.J Am Heart Assoc, 8,7(13):e009174.

[4] ABDU F A, MOHAMMED A Q, LIU L, et al.Myocardial infarction with nonobstructive coronary arteries (MINOCA):a review of the current position.Cardiology, 0,5(9):543-552.

[5] EGGERS K M, BARON T, HIORT M, et al.Clinical and prognostic implications of C-reactive protein levels in myocardial infarction with nonobstructive coronary arteries.Clin Cardiol, 1,4(7):1019-1027.

[6] HJORT M, EGGERS K M, LINDHAGEN L, et al.Increased inflammatory activity in patients 3 months after myocardial infarction with nonobstructive coronary arteries.Clin Chem, 9,5(8):1023-1030.

[7] NORDENSKJLD A M, BARON T, EGGERS K M, et al.Predictors of adverse outcome in patients with myocardial infarction with non-obstructive coronary artery (MINOCA) disease.Int J Cardiol, 8,1:18-23.

[8] GRDAL A, KESKIN K, SIGˇIRCI S, et al.Prognostic value of the neutrophil-to-lymphocyte ratio in patients with myocardial infarction with non-obstructive coronary arteries.Angiology, 0,1(9):812-816.

[9] TAMIS-HOLLAND J E, JNEID H, REYNOLDS H R, et al.Contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease:a scientific statement from the American Heart Association.Circulation, 9,9(18):e891-e908.

[10] 李祎铭, 姜厚望, 李海燕, 等.《AHA冠状动脉非阻塞性心肌梗死诊断和管理科学声明》解读.中西医结合心脑血管病杂志, 1,9(3):353-357.LI Y M, JIANG H W, LI H Y.Interpretation of “contemporary diagnosis and management of patients with myocardial infarction in the absence of obstructive coronary artery disease:a scientific statement from the American Heart Association”.Chin J Integr Med Cardio-Cerebrovasc Dis, 1,9(3):353-357.

[11] TALEBI S, JADHAV P, TAMIS-HOLLAND J E, Myocardial infarction in the absence of obstructive coronary artery disease (MINOCA):a review of the present and preview of the future.Curr Atheroscler Rep, 1,3(9):49.

[12] SZODORAY P, TIMAR O, VERES K, et al.TH1/TH2 imbalance, measured by circulating and intracytoplasmic inflammatory cytokines--immunological alterations in acute coronary syndrome and stable coronary artery disease.Scand J Immunol, 6,4(3):336-344.

[13] MORENO P R.Pathophysiology of plaque disruption and thrombosis in acute ischemic syndromes.J Stroke Cerebrovasc Dis, 1,0(2 Pt 2):2-9.

[14] MONTONE R A, NICCOLI G, RUSSO M, et al.Clinical, angiographic and echocardiographic correlates of epicardial and microvascular spasm in patients with myocardial ischaemia and non-obstructive coronary arteries.Clin Res Cardiol, 0,9(4):435-443.

[15] OHYAMA K, MATSUMOTO Y, TAKANAMI K, et al.Coronary adventitial and perivascular adipose tissue inflammation in patients with vasospastic angina.J Am Coll Cardiol, 8,1(4):414-425.

[16] ITOH T, MIZUNO Y, HARADA E, et al.Coronary spasm is associated with chronic low-grade inflammation.Circ J, 7,1(7):1074-1078.

[17] HUNG M Y, WU Y H, BAMODU O A, et al.Activation of the monocytic α7 nicotinic acetylcholine receptor modulates oxidative stress and inflammation-associated development of coronary artery spasm via a p38 MAP-kinase signaling-dependent pathway.Free Radic Biol Med, 8,0:266-276.

[18] KUGIYAMA K, OTA Y, KAWANO H, et al.Increase in plasma levels of secretory type Ⅱ phospholipase A2 in patients with coronary spastic angina.Cardiovasc Res, 0,7(1):159-165.

[19] ARIBAS E, ROETERS VAN LENNEP J E, ELIAS-SMALE S E, et al.Prevalence of microvascular angina among patients with stable symptoms in the absence of obstructive coronary artery disease:a systematic review.Cardiovasc Res, 2,8(3):763-771.

[20] SINHA A, MA Y, SCHERZER R, et al.Role of T-cell dysfunction, inflammation, and coagulation in microvascular disease in HIV.J Am Heart Assoc, 6,5(12):e004243.

[21] ZANATTA E, COLOMBO C, D'AMICO G, et al.Inflammation and coronary microvascular dysfunction in autoimmune rheumatic diseases.Int J Mol Sci, 9,0(22):5563.

[22] VERMA S, KULISZEWSKI M A, LI S H, et al.C-reactive protein attenuates endothelial progenitor cell survival, differentiation, and function:further evidence of a mechanistic link between C-reactive protein and cardiovascular disease.Circulation, 4,9(17):2058-2067.

[23] PASUPATHY S, AIR T, DREYER R P, et al.Systematic review of patients presenting with suspected myocardial infarction and nonobstructive coronary arteries.Circulation, 5,1(10):861-870.

[24] OIKONOMOU E, LEOPOULOU M, THEOFILIS P, et al.A link between inflammation and thrombosis in atherosclerotic cardiovascular diseases:clinical and therapeutic implications.Atherosclerosis, 0,9:16-26.

[25] GERHARDT T, HAGHIKIA A, STAPMANNS P, et al.Immune mechanisms of plaque instability.Front Cardiovasc Med, 1,8:797046.

[26] KLEINBONGARD P, HEUSCH G.A fresh look at coronary microembolization.Nat Rev Cardiol, 2,9(4):265-280.

[27] KHAN A, LAHMAR A, RIASAT M, et al.Myocardial infarction with non-obstructive coronary arteries:an apdated overview of pathophysiology, diagnosis, and management.Cureus, 2,4(3):e23602.

[28] HAYES S N, KIM E S H, SAW J, et al.Spontaneous coronary artery dissection:current state of the science:a scientific statement from the american heart association.Circulation, 8,7(19):e523-e557.

[29] PITLIYA A, DATTA S, KALAYCI A, et al.Eosinophilic inflammation in spontaneous coronary artery dissection:a potential therapeutic target?.Med Hypotheses, 8,1:91-94.

[30] 吐尔孙阿依·依斯米提拉, 阿里米江·阿布里米提, 穆叶赛·尼加提.急性心肌梗死患者C反应蛋白与白蛋白比值与冠状动脉狭窄程度的相关性.中国动脉硬化杂志, 1,9(10):869-874.TUERSUNAYI Y, ALIMIJIANG A, MUYESAI N.Relationship between C-reactive protein to albumin ratio and the degree of coronary artery disease in patients with acute myocardial infarction.Chin J Arterioscler, 1,9(10):869-874.

[31] CILIBERTI G, COIRO S, TRITTO I, et al.Predictors of poor clinical outcomes in patients with acute myocardial infarction and non-obstructed coronary arteries (MINOCA).Int J Cardiol, 8,7:41-45.

[32] TAMHANE U U, ANEJA S, MONTGOMERY D, et al.Association between admission neutrophil to lymphocyte ratio and outcomes in patients with acute coronary syndrome.Am J Cardiol, 8,2(6):653-657.

[33] RIDKER P M.From C-reactive protein to interleukin-6 to interleukin-1:moving upstream to identify novel targets for atheroprotection.Circ Res, 6,8(1):145-156.

[34] DATE H, IMAMURA T, SUMI T, et al.Effects of interleukin-6 produced in coronary circulation on production of C-reactive protein and coronary microvascular resistance.Am J Cardiol, 5,5(7):849-852.

[35] DA SILVA G M, DA SILVA M C, NASCIMENTO D V G, et al.Nitric oxide as a central molecule in hypertension:focus on the vasorelaxant activity of new nitric oxide donors.Biology (Basel), 1,0(10):1041.

[36] HUNG M J, CHERNG W J, HUNG M Y, et al.Interleukin-6 inhibits endothelial nitric oxide synthase activation and increases endothelial nitric oxide synthase binding to stabilized Caveolin-1 in human vascular endothelial cells.J Hypertens, 0,8(5):940-951.

[37] ABDU F A, LIU L, MOHAMMED A Q, et al.Effect of secondary prevention medication on the prognosis in patients with myocardial infarction with nonobstructive coronary artery disease.J Cardiovasc Pharmacol, 0,6(6):678-683.

[38] KANG W Y, JEONG M H, AHN Y K, et al.Are patients with angiographically near-normal coronary arteries who present as acute myocardial infarction actually safe?.Int J Cardiol, 1,6(2):207-212.

[39] EGGERS K M, HADZIOSMANOVIC N, BARON T, et al.Myocardial infarction with nonobstructive coronary arteries:the importance of achieving secondary prevention targets.Am J Med, 8,1(5):524-531.

[40] SLUCHINSKI S L, PITUSKIN E, BAINEY K R, et al.A review of the evidence for treatment of myocardial infarction with nonobstructive coronary arteries.CJC Open, 0,2(5):395-401.

[41] PAOLISSO P, BERGAMASCHI L, SATURI G, et al.Secondary prevention medical therapy and outcomes in patients with myocardial infarction with non-obstructive coronary artery disease.Front Pharmacol, 0,0:1606.

[42] BRYNIARSKI P, NAZIMEK K, MARCINKIEWICZ J.Immunomodulatory activity of the most commonly used antihypertensive drugs-angiotensin converting enzyme inhibitors and angiotensin Ⅱ receptor blockers.Int J Mol Sci, 2,3(3):1772.

Get Citation

FEI Sifan, JIA Fang, ZHANG Sheng. Role of inflammation in myocardial infarction with non-obstructive coronary arteries[J]. Editorial Office of Chinese Journal of Arteriosclerosis,2023,31(6):533-538.

Copy

Article Metrics

Abstract:
PDF:
HTML:
Cited by:

History

Received:May 17,2022
Revised:September 01,2022
Adopted:
Online: June 12,2023
Published:

Policies & Instructions

Get Citation

Share

Article Metrics

History

Article QR Code